Catherine Schnabel

Dr. Catherine Schnabel brings over 20 years of scientific and leadership experience in the biomedical and molecular diagnostics industries. Prior to joining Nucleix, Cathy was the Chief Scientific Officer of Biotheranostics, where she led the development and translation of proprietary molecular signatures for breast cancer and metastatic disease, including incorporation of these novel technologies into clinical practice guidelines. An industry leader in evidence-based diagnostics, she has authored over 100 peer reviewed publications and disclosures and is an inventor on several patents. Cathy previously held research positions at Genentech and Genoptix and gained medical affairs expertise at Amylin Pharmaceuticals, investigating and launching first-in-class therapies and biomarkers. Cathy holds a Ph.D. in cell and developmental biology from the Center for Advanced Biotechnology and Medicine at Rutgers University and was a fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University.